Silexion Therapeutics Corp (NASDAQ:SLXN) has announced breakthrough preclinical results for its next-generation RNA ...

Arrowhead Pharmaceuticals, Inc.'s deal with Sarepta expands its pipeline, but limited plozasiran market and competition ...

Results from a clinical trial led by researchers from Queen Mary University of London, published today in JAMA, show that ...

TransCode Therapeutics (NASDAQ: RNAZ) , has appointed Dr. Phillip D. Zamore, a leading figure in RNA interference (RNAi) research and co-founder of A ...

A start-up that launched only 8 months ago has attracted the attention of Biogen, a major developer of neurological drugs.

TransCode Therapeutics, Inc. , a clinical-stage oncology company developing RNA-targeted therapeutics for the treatment of cancer, today announced the appointment of Phillip D. Zamore, Ph.D., to its ...

Biogen will pay City Therapeutics $46m, which includes $16m upfront and $30m investment for a convertible note.

Biogen ( NASDAQ: BIIB) and City Therapeutics signed a collaboration to develop novel RNA interference ( (RNAi)) therapies ...

CAMBRIDGE, Mass., May 27, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and City Therapeutics, Inc., a privately held biopharmaceutical company leading the future of RNA interference ...

The expression of symptoms of viral infections is a byproduct of complex virus-host molecular pathways. These remain largely ...

Several genetic studies have attempted to explore the fungal factors involved in antiviral responses, but the exact genes and ...